TOT BIOPHARM International Co. Ltd. (1875) AI Stock Analysis

• Market Cap: HK$1.50B
• Dividend Yield: N/A
• Average Volume (3M): 240.51K
• Price to Earnings (P/E): 184.8
• Beta (1Y): 0.48
• Revenue Growth: 9.41%
• EPS Growth: -32.69%
• Country: HK
• Employees: 611
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.01
• Shares Outstanding: 772,787,900
• 10 Day Avg. Volume: 141,880
• 30 Day Avg. Volume: 240,506
• PEG Ratio: -0.18
• Price to Book (P/B): 1.67
• Price to Sales (P/S): 1.11
• P/FCF Ratio: -170.02
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: HK$2.00 ▲(1.01% Upside)

The overall stock score is primarily influenced by strong financial performance, despite liquidity concerns. Technical analysis indicates bearish momentum, and valuation metrics suggest the stock may be overvalued. The absence of earnings call and corporate events data did not impact the score.

Positive Factors

Revenue Growth

TOT BIOPHARM's revenue growth reflects its expanding market reach and successful product adoption, crucial for long-term sustainability in the competitive biopharmaceutical industry.

Balance Sheet Health

A solid balance sheet with low debt enhances financial stability, providing the company with the flexibility to invest in R&D and strategic initiatives, crucial for long-term growth.

Profitability Improvement

Improved profitability margins indicate enhanced operational efficiency and cost management, which are vital for sustaining competitive advantage and shareholder value.

Negative Factors

Negative Free Cash Flow

Persistent negative Free Cash Flow can strain the company's liquidity, limiting its ability to fund operations and invest in growth opportunities, posing a risk to financial health.

Liquidity Concerns

Liquidity issues, highlighted by negative Free Cash Flow, could affect the company's ability to meet short-term obligations, potentially impacting operational stability.

Earnings Volatility

Past earnings volatility suggests potential risks in maintaining consistent growth, which could affect investor confidence and the company's ability to secure funding.

TOT BIOPHARM International Co. Ltd. Business Overview & Revenue Model

Company Description

TOT BIOPHARM International Co. Ltd. (1875) is a biopharmaceutical company based in China that specializes in the research, development, manufacturing, and marketing of innovative therapies, particularly in the fields of oncology and immunology. The company focuses on biologics and small molecule drugs, with a strong emphasis on developing novel treatments for cancer and autoimmune diseases. Its core products include monoclonal antibodies and other biopharmaceuticals designed to improve patient outcomes and quality of life.

How the Company Makes Money

TOT BIOPHARM generates revenue primarily through the sale of its biopharmaceutical products, which include proprietary drugs and therapies developed in-house. The company has a diverse revenue model that includes direct sales to hospitals and clinics, as well as partnerships with other pharmaceutical companies for co-development and distribution. Additionally, TOT BIOPHARM may earn revenue through licensing agreements, where it licenses its technology or products to other companies for further development or commercialization. Significant partnerships with research institutions and collaborations with global pharmaceutical firms also contribute to the company's earnings, enhancing its market reach and capabilities in product development.

TOT BIOPHARM International Co. Ltd. Financial Statement Overview

Summary

TOT BIOPHARM International Co. Ltd. has shown a strong recovery in revenue and profitability with improved margins and financial health. The balance sheet is solid with low debt levels and positive equity returns. However, liquidity remains a concern due to negative Free Cash Flow, indicating potential cash management challenges.

Income Statement

The company has shown a significant improvement in revenue and profitability. Gross Profit Margin and Net Profit Margin have improved substantially from negative to positive, indicating a turnaround. The EBIT and EBITDA margins have moved from negative to positive, highlighting improved operational efficiency. However, the company faced challenges in previous years with negative growth, which could indicate potential volatility.

Balance Sheet

The balance sheet is strong with a relatively low Debt-to-Equity Ratio, indicating prudent financial leverage. The Return on Equity has turned positive, suggesting effective use of shareholder funds. The Equity Ratio is stable, showing a solid equity base. The company has maintained a healthy cash position over the years, enhancing financial stability.

Cash Flow

The cash flow statements show some concerns. The Free Cash Flow remains negative, impacting the cash flow score. However, the company has improved its Operating Cash Flow to Net Income Ratio, reflecting better cash generation from operations. Continued negative Free Cash Flow indicates potential liquidity challenges, although the company has managed its financing activities to maintain cash reserves.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.07B	1.10B	780.63M	442.18M	76.33M	22.49M
Gross Profit	758.56M	782.43M	573.99M	370.62M	27.47M	15.53M
EBITDA	43.83M	84.96M	10.45M	-5.41M	-224.51M	-254.71M
Net Income	7.26M	34.76M	-37.76M	-49.92M	-261.22M	-288.50M
Balance Sheet
Total Assets	1.48B	1.51B	1.43B	1.26B	710.26M	641.18M
Cash, Cash Equivalents and Short-Term Investments	383.98M	381.26M	351.60M	517.63M	155.38M	225.53M
Total Debt	397.20M	395.47M	345.65M	289.53M	208.56M	7.41M
Total Liabilities	744.74M	779.12M	739.41M	546.59M	375.17M	58.83M
Stockholders Equity	731.68M	729.65M	686.69M	713.88M	335.09M	582.36M
Cash Flow
Free Cash Flow	48.42M	-7.17M	-146.77M	-180.19M	-290.45M	-285.30M
Operating Cash Flow	123.43M	116.40M	56.43M	59.93M	-175.14M	-263.12M
Investing Cash Flow	-80.23M	-122.50M	-164.10M	-282.76M	-108.39M	12.53M
Financing Cash Flow	-7.09M	34.18M	38.23M	481.24M	212.08M	-61.71M

TOT BIOPHARM International Co. Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.98
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1875, the sentiment is Positive. The current price of 1.98 is above the 20-day moving average (MA) of 1.80, above the 50-day MA of 1.95, and below the 200-day MA of 2.03, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 62.24 is Neutral, neither overbought nor oversold. The STOCH value of 98.85 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1875.

TOT BIOPHARM International Co. Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	58 Neutral	HK$1.50B	184.76	0.99%	―	9.41%	-32.69%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
6622	47 Neutral	HK$1.66B	-5.50	-14.84%	―	-38.38%	-22.12%
2181	45 Neutral	HK$2.19B	-73.61	-25.72%	―	178.36%	86.74%
6978	37 Underperform	HK$1.75B	-6.57	―	―	―	27.90%
2511	36 Underperform	HK$1.33B	-3.75	-67.27%	―	―	47.42%
2185	32 Underperform	HK$1.37B	-14.16	-14.87%	―	―	22.65%

TOT BIOPHARM International Co. Ltd. Corporate Events

BioDlink Reports 23% Revenue Decline Amidst Market Competition

BioDlink International Company Limited, along with its subsidiaries, operates in the biotechnology sector, focusing on the development and commercialization of biopharmaceutical products. The company is listed on the Hong Kong Stock Exchange and has a significant shareholder, Center Laboratories, Inc., listed on the Taipei Exchange. The company announced a 23% decrease in revenue for the nine months ending September 30, 2025, compared to the same period in 2024, due to increased market competition for its self-developed products. This financial update, extracted from unaudited management accounts, highlights fluctuating operational results, advising shareholders and investors to exercise caution.

BioDlink Announces Leadership Changes Amidst Resignations

BioDlink International Company Limited announced changes in its leadership, with Dr. Liu and Ms. Yeh-Huang resigning from their respective positions due to family reasons. This reshuffling may impact the company’s strategic direction and governance, as it involves key roles such as the executive director, chief executive officer, and members of the Strategy and ESG Committee.

BioDlink International Announces Leadership Restructuring

BioDlink International Company Limited, a Hong Kong-based company, announced significant changes in its leadership structure. Mr. Fu, Shan has been re-designated from a non-executive director to an executive director, continuing his role as chairperson of the Board and various committees. This change positions Mr. Fu to lead and oversee the management and development of the company, potentially impacting its strategic direction and stakeholder relations.

BioDlink International Announces Board and Committee Restructuring

BioDlink International Company Limited, incorporated in Hong Kong, has announced changes to its board of directors and the composition of its board committees. Effective from October 11, 2025, Mr. Fu Shan will serve as the Chairperson of the Strategy and ESG Committee, while Dr. Liu Weidong, Ms. Sun Hui, Mr. Zhang Qing, and Dr. Gu Xuelin will take on various roles across the Audit and Connected Transactions Review, Remuneration, and Nomination Committees. These changes are expected to enhance the governance and strategic oversight of the company.